文献速递胸部肿瘤放疗放疗物理与技术

早期肺癌SBRT中主动保护免疫系统的随机II期研究

First Measurement: Proactively Sparing the Immune System During Stereotactic Body Radiation Therapy to Early-Stage Lung Cancer-A Randomized Phase II Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-07-22

单中心II期随机试验纳入51例早期非小细胞肺癌(IA-IB/IIA)患者,比较优化SBRT(降低血液、骨髓、淋巴结受量)与标准SBRT对放疗诱导淋巴细胞杀伤(RILK)及不良事件的影响。优化组淋巴细胞下降幅度更小,总体改善13.4%(95%CI 2.8-24.0;P=.01),中央型肿瘤改善29.5%(95%CI 10.1-48.9;P=.004);标准组3级及以上淋巴细胞减少发生率为15.4%,优化组未见发生。

要点

  • 优化SBRT可显著减少早期肺癌患者SBRT后淋巴细胞下降,中央型肿瘤获益最大。
  • 标准组3级及以上淋巴细胞减少发生率为15.4%,优化组为0(风险差-15.4%;95%CI -29.2%至-1.5%;P=.04)。
  • 优化组与标准组3级及以上不良事件无差异,安全性相当。

核心结论

  • 在早期非小细胞肺癌SBRT中,对免疫富集器官实施显著剂量降低是可行的,安全性相当,且较标准治疗明显保护淋巴细胞。
  • 心脏、大血管、胸椎和淋巴结受量与RILK显著相关。

研究设计与样本

  • 单中心II期随机试验,纳入51例早期非小细胞肺癌(IA-IB/IIA)患者,随机接受优化SBRT或标准SBRT,两者均遵循RTOG 0813/0915指南。
  • 于基线、治疗当天、治疗后4周和6个月采集外周血。

主要发现

  • 优化组与标准组相比,心脏、淋巴结和胸椎的积分剂量、V5和V10平均降低幅度分别为21%-68%(P=.04-.36)、37%-68%(P<.001-.01)和57%-92%(P<.001-.002)。
  • SBRT后即刻、4周和6个月淋巴细胞绝对计数较基线变化:优化组-16%、-22%、-16%;标准组-31%、-34%、-26%;优化治疗总体改善13.4%(95%CI 2.8-24.0;P=.01)。
  • 中央型肿瘤改善最大:优化组-8%、-18%、-14%;标准组-39%、-43%、-47%;总体改善29.5%(95%CI 10.1-48.9;P=.004)。
  • SBRT后3级及以上淋巴细胞减少:标准组15.4%,优化组0(风险差-15.4%;95%CI -29.2%至-1.5%;P=.04)。
  • SBRT后淋巴细胞绝对计数升高的患者比例:标准组11.5%(仅PTV<20 cm3的外周型亚组),优化组32%(所有亚组)。

关键数值与推荐

  • 优化SBRT在RTOG 0813/0915指南基础上进一步降低血液、骨髓和淋巴结剂量。
  • 主要免疫学终点为外周血淋巴细胞绝对计数变化,于基线、当天、4周和6个月评估。
  • 3级及以上不良事件两组无差异。

临床怎么用

  • 对早期非小细胞肺癌行SBRT时,可在满足RTOG 0813/0915覆盖前提下主动降低心脏、大血管、胸椎和淋巴结受量以保护淋巴细胞。
  • 中央型肿瘤患者从优化计划中淋巴细胞保护获益更明显。
  • 优化计划未增加3级及以上不良事件,安全性可接受。

局限性

  • 单中心II期研究,样本量51例。
  • 生存分析为探索性,事件无生存P=.10、总生存P=.14,均未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Minimizing radiation induced-lymphocyte-kill (RILK), a key immune-suppressive effect of radiation therapy (RT) to augment tumor-specific immunity is timely and important. We assessed RT dose sparing to blood/immune-rich organs beyond Radiation Therapy Oncology Group (RTOG) criteria, and its effect on RILK, and adverse events. METHODS AND MATERIALS: We conducted a single-institution phase II randomized trial enrolling 51 early-stage non-small cell lung cancer patients (IA-IB/IIA), to be treated with stereotactic body radiation therapy (SBRT) to evaluate the effect of dose reduction to immune rich organs on RILK, focusing on lymphocytes as primary immune cells. Participants were randomized to optimized-SBRT (reducing dose to blood, bone-marrow, lymph-nodes) or standard-SBRT, both following Radiation Therapy Oncology Group 0813/0915 guidelines. Peripheral blood was collected at baseline, same day, 4 weeks and 6 months posttreatment. RESULTS: Average percentage reductions in integral-dose, V5, and V10 to heart, lymph-nodes, and thoracic-vertebrae in the optimized arm versus standard arm were 21%-68% (P = .04-.36), 37%-68% (P < .001-.01), and 57%-92% (P < .001-.002), respectively. Absolute lymphocyte count changes from baseline at immediate, 4 weeks, and 6 months post-SBRT were: optimized: -16%, -22%, -16%; standard: -31%, -34%, -26%; overall improvement: 13.4% (95% CI, 2.8-24.0; P = .01) with optimized-treatment. Central tumors had the largest improvement: optimized: -8%, -18%, -14%; standard: -39%, -43%, -47%; overall improvement: 29.5% (95% CI, 10.1-48.9; P = .004). Post-SBRT grade 3 or higher lymphopenia occurred in 15.4% of standard arm patients but was absent in the optimized arm (risk difference -15.4%; 95% CI, -29.2% to -1.5%; P = .04). Standard arm: 11.5% (only peripheral with PTV < 20 cm3 group) and optimized arm: 32% (all subgroups) patients had a post-SBRT ALC increase. Dose to immune-rich organs (heart, great vessels, thoracic-spine, and lymph-nodes) significantly correlated with RILK. There was no difference in grade 3+ adverse events between groups. Exploratory analysis: a trend toward increased event-free-survival (2-year: 75.0% [SE = 10.8%] versus 59.8% [SE = 11.2%], P = .10) and overall survival (2-year: 93.4% [SE = 6.1%] versus 69.4% [SE = 10.5%], P = .14) was observed with optimized planning compared to standard planning in treatment-naïve patients. CONCLUSIONS: Significant RT dose reductions to immune rich organs in lung SBRT with comparable-safety is achievable, markedly preserving lymphocytes compared to standard of care.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Wijesooriya K, Nguyen C, Conaway MR, et al. First Measurement: Proactively Sparing the Immune System During Stereotactic Body Radiation Therapy to Early-Stage Lung Cancer-A Randomized Phase II Study. Int J Radiat Oncol Biol Phys. 2026. PMID: 42486309. doi:10.1016/j.ijrobp.2026.07.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。